It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Age-associated microglial dysfunction contributes to the accumulation of amyloid-β (Aβ) plaques in Alzheimer’s disease. Although several studies have shown age-related declines in the phagocytic capacity of myeloid cells, relatively few have examined phagocytosis of normally aged microglia. Furthermore, much of the existing data on aging microglial function have been generated in accelerated genetic models of Alzheimer’s disease. Here we found that naturally aged microglia phagocytosed less Aβ over time. To gain a better understanding of such dysfunction, we assessed differences in gene expression between young and old microglia that either did or did not phagocytose Aβ. Young microglia had both phagocytic and neuronal maintenance signatures indicative of normal microglial responses, whereas, old microglia, regardless of phagocytic status, exhibit signs of broad dysfunction reflective of underlying neurologic disease states. We also found downregulation of many phagocytic receptors on old microglia, including TREM2, an Aβ phagocytic receptor. TREM2 protein expression was diminished in old microglia and loss of TREM2+ microglia was correlated with impaired Aβ uptake, suggesting a mechanism for phagocytic dysfunction in old microglia. Combined, our work reveals that normally aged microglia have broad changes in gene expression, including defects in Aβ phagocytosis that likely underlies the progression to neurologic disease.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Cincinnati College of Medicine, Department of Pediatrics, Cincinnati, USA (GRID:grid.24827.3b) (ISNI:0000 0001 2179 9593); Division of Immunobiology of Cincinnati Children’s Hospital Medical Center, Cincinnati, USA (GRID:grid.239573.9) (ISNI:0000 0000 9025 8099); Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine, Immunology Graduate Program, Cincinnati, USA (GRID:grid.24827.3b) (ISNI:0000 0001 2179 9593)
2 Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine, Immunology Graduate Program, Cincinnati, USA (GRID:grid.24827.3b) (ISNI:0000 0001 2179 9593); University of Cincinnati College of Medicine, Department of Internal Medicine, Division of Hematology/Oncology, Cincinnati, USA (GRID:grid.24827.3b) (ISNI:0000 0001 2179 9593)
3 Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine, Immunology Graduate Program, Cincinnati, USA (GRID:grid.24827.3b) (ISNI:0000 0001 2179 9593); Janssen Research and Development, Spring House, USA (GRID:grid.497530.c) (ISNI:0000 0004 0389 4927)